MDL | MFCD00866585 |
---|---|
Molecular Weight | 293.45 |
Molecular Formula | C21H27N |
SMILES | CC(N1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)CC1)(C)C |
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease [1] .
NMDA Receptor |
Budipine (s.c., 30 μg/24 h, 11 days) is a substrate of P-glycoprotein (P-gp) and is actively transported out of the brain through the blood–brain barrier back into the blood plasma [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Male abcblab(-/-) mice
[1]
Male abcblab(-/-) mice (n=8, weight 29.0 g) and FVB/N wild-type mice (n =8, weight 28.0 g) |
Dosage: |
30 μg
(Budipine is dissolved in 0.9% sodium chloride and 0.5% ethanol) |
Administration: | subcutaneous injections, continuously delivered 30 μg over 24 h, 11 days |
Result: |
Increased the cerebrum concentration for 3.1 times high in knock-out mice after an 11-day continuous administration.
Showed no significant differences in plasma, spleen, kidney and liver. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 25 mg/mL ( 85.19 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.4077 mL | 17.0387 mL | 34.0774 mL |
5 mM | 0.6815 mL | 3.4077 mL | 6.8155 mL |
10 mM | 0.3408 mL | 1.7039 mL | 3.4077 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.52 mM); Clear solution